# A Post-Authorization, Long-term Study of Ozanimod Real-world Safety

> **NCT05605782** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 9000 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05605782
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-02
- **Primary completion:** 2033-07-26
- **Final completion:** 2033-07-26
- **Target enrollment:** 9000 (ACTUAL)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05605782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05605782, "A Post-Authorization, Long-term Study of Ozanimod Real-world Safety". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05605782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*